Primary Sclerosing Cholangitis
Official guideline from the American College of Gastroenterology.
summary by Gaurav Ghosh, MD Shawn Shah, MD
Diagnosis
Imaging
Biopsy
Liver biopsy not necessary to establish PSC diagnosis if cholangiographic findings are diagnostic.
Management
ERCP
ERCP + balloon dilation recommended if dominant stricture (CBD <1.5 mm, hepatic ducts <1.0 mm) and pruritus, and/or cholangitis.
If dominant stricture on imaging, should do ERCP + cytology, biopsies, and FISH to exclude cholangiocarcinoma.
Should give prophylactic antibiotics before ERCP to prevent post-ERCP cholangitis.
General
If mild pruritus, should treat with skin emollients and/or antihistamines.
If moderate pruritus, should treat with bile acid sequestrants (e.g., cholestyramine 4–16 g/d); if ineffective or not tolerated, can consider rifampin 150–300 mg BID (monitor for hepatotoxicity) or naltrexone (up to 50 mg/d).
Recommend screening for varices if advanced PSC or platelets < 150K × 10³/dL.
At PSC diagnosis, recommend DEXA scan and repeat at 2-4-year intervals.
Special Situations
Liver Transplant
Liver transplant recommended (when possible) over medical therapy or surgical drainage in PSC with decompensated cirrhosis (prolongs survival).
Medical Treatment
Special Situations
If age <25 or higher-than-expected aminotransferases (5x ULN), recommend testing for AIH (~10% prevalence in PSC).
HPB Malignancies and Gallbladder Disease
Consider US or MRCP + serial CA 19-9 every 6-12 months to screen for cholangiocarcinoma (10-year cumulative risk 8%).
PSC and IBD
In PSC + IBD, recommend annual CRC screening with chromoendoscopy (4-5x increased dysplasia/cancer risk with PSC + IBD as compared to IBD without PSC).
At time of PSC dx, full colonoscopy + bx recommended to evaluate for IBD.
What do the icons mean?
How strong is the ACG's recommendation?
Strong recommendation
Intervention's desirable effects clearly outweigh undesirable effects.Moderate recommendation
Further research likely to impact confidence in estimate of effect.Conditional recommendation
Uncertainty in tradeoffs between desirable & undesirable effects of intervention.Weak recommendation
Uncertainty in tradeoffs between desirable & undesirable effects of intervention.High quality evidence
Further research unlikely to change guideline authors' confidence in estimate of effect.Moderate-high quality evidence
Between high and moderate levels of evidence.Moderate quality evidence
Further research likely to impact confidence in estimate of effect.Low quality evidence
Further research expected to have important impact in confidence in estimate of effect.Very low quality evidence
Effect is very uncertain.Literature